Adjacent Evidence Brief: Statin

Research Synthesis: Statin

Abstract

This paper synthesizes evidence on Statin across 62 accepted source papers and 1367 high-confidence extracted claims.

The evidence profile contains 4 direct clinical sources, 58 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are summarized in the contextual adjacent evidence, longevity and cardiometabolic outcome classes, null signals in the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that Statin remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

Research Question

For Statin, what does the retained evidence show about prognostic or risk-marker associations, causal or mechanistic evidence, treatment or intervention relevance across treatment or intervention-response evidence, adjacent clinical-context evidence, biology-mechanism and molecular-context evidence, and are those outcome-class source-level signals directionally consistent enough for clinical actionability once unclear direction coding, adjacent/contextual source roles, and directness limits are considered?

Introduction

Aging biology and the compression of morbidity have become central organizing questions for translational medicine, with the proposition that intervening on shared upstream mechanisms could delay multiple chronic conditions simultaneously rather than treating each disease in isolation. Within this frame, pharmacologic candidates that are already widely deployed for one indication carry a distinctive appeal, because their safety record, dosing, and population exposure are partially established. Statins, the class of hmg coa reductase inhibitor drugs originally developed for low-density lipoprotein cholesterol lowering, sit at the center of this debate, and the question of whether their benefits might extend to broader aging-relevant endpoints has been actively pursued for over a decade. The clinical stakes are not trivial: even modest shifts in healthspan or lifespan at the population level would translate into substantial years of life and disability-free survival. Yet the urgency is matched by uncertainty, and recent calls for rigorous evaluation have emphasized that the case for repurposing statins into an aging indication remains incompletely defined.

Several unresolved questions thread through this evidence base and are not adequately settled by any single trial or by the corpus taken as a whole. First, the translation from mechanistic biomarker shifts to functional aging outcomes remains uncertain, and the surrogate endpoint caution that Ioannidis 2005 raises applies with particular force when short-term biochemical changes are extrapolated to long-horizon endpoints such as lifespan. Second, the tradeoffs are not symmetric across populations: in Lee 2023 dialysis patients and in Guo 2019 patients aged 80 and over, safety and adherence profiles diverge from the cardiovascular prevention populations in which statins were initially validated. Third, dose-response, duration, and population specificity, including genotype interactions noted in Asiimwe 2024a and Asiimwe 2024b, all appear to moderate any signal, suggesting that the question of whether statins can extend healthspan may not have a single answer.

Against this background, the present synthesis deliberately separates clinical from mechanistic inference, treats surrogate endpoint patterns as hypothesis-generating rather than confirmatory in line with the cautionary framing of Ioannidis 2005, and organizes evidence by outcome class rather than by chronology. By weighting direct randomized designs separately from observational and review-class sources, and by surfacing the within-class tensions and cross-domain contradictions that the retained corpus exposes, the analysis aims to define the boundary conditions under which the statins aging case currently holds, and to clarify which gaps an aging-focused trial would need to close. The retained statins corpus supports translation only conditionally, and the question of broader healthspan or lifespan benefit appears to remain open rather than answered.

Background

The geroscience hypothesis holds that interventions targeting the molecular hallmarks of aging — mitochondrial dysfunction, cellular senescence, dysregulated nutrient sensing, and altered proteostasis — could compress multimorbidity in later life rather than treating each disease in isolation. Within this framework, statins are an attractive candidate because their primary pharmacological target, HMG-CoA reductase inhibition, intersects several hallmark pathways beyond low-density lipoprotein cholesterol (LDL-C) lowering, including mevalonate-derived isoprenoid signalling, mitochondrial respiratory chain assembly, and NLRP3 inflammasome priming. Regulatory bodies have so far authorised statins almost exclusively for lipid-driven cardiovascular risk reduction, leaving their broader geroscience indications — cognitive preservation, frailty attenuation, and mortality in non-cardiovascular populations — outside formal approval pathways. The implication is that any aging-related use case for statins has to be argued from off-label evidence streams and is therefore inherently indirect. This synthesis examines what the curated corpus contributes to that argument, deliberately separating directly tested RCT endpoints from observational signals that may be hypothesis-generating only.

Five methodological problems recur across the retained evidence and constrain any claim of broad aging benefit. First, surrogate-endpoint reliance is heavy: surrogate endpoints are known not to guarantee hard-outcome validity (Ioannidis 2005), and biomarker-level drops in amyloid carriers or lipid intermediates may not translate to clinical events. Second, population heterogeneity is large — older adults, dialysis patients, HIV-positive cohorts, cancer patients, and post-COVID-19 cohorts — and pooling across them obscures indication-specific effects. Third, treatment duration rarely matches the latency implied by an aging endpoint; even the 6-month Rustamzadeh 2024 protocol is short relative to dementia pathogenesis. The synthesis therefore keeps outcome-class distinctions explicit: review-class evidence should be treated as hypothesis-generating only, and direct RCT evidence remains the only basis on which substantive claims about statins in aging populations can rest.

Evidence Context

The evidence context combines established clinical use, adjacent human evidence, animal or cellular mechanisms, and open translational questions. Separating those evidence types prevents later sections from collapsing unlike forms of support into a single verdict. The central research problem remains whether mechanistic plausibility and source-traced findings converge strongly enough to justify further clinical testing while keeping patient-facing claims conservative.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-statins-v06-DAILY-2026-07-16T02-15-58Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-16.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• statin AND aging AND human
• statin AND (RCT OR clinical trial OR randomized)
• (atorvastatin OR rosuvastatin OR simvastatin) AND (longevity OR healthspan OR mortality)
• statin AND elderly AND (frailty OR sarcopenia OR muscle)
• statin AND primary prevention AND cardiovascular
• statin AND (myopathy OR myalgia OR adverse) AND elderly
• statin AND mTOR AND mechanism
• statin AND (LDL cholesterol OR lipid lowering) AND clinical
• statin AND (PROSPER OR HOPE-3 OR JUPITER OR STAREE) AND outcomes
• statin AND (4S OR HPS OR CTT OR CTSU) AND mortality
• (... 7 additional queries; see methods_pack.json for the full list)

Eligibility criteria

• Sources whose primary content addresses statins.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

Of 62 records retrieved, 62 were screened against the eligibility criteria, 62 were included in the synthesis, and 0 were excluded at full-text review. Reasons for exclusion are summarised below.

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Directness coding criteria

A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

Risk-of-bias appraisal

Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated risk_of_bias.json rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Evidence Landscape

Numeric verification note: Karkeet 2022 reported a non-significant mapped comparison (p = 0.009); this synthesis treats that mapped comparison, not every within-source contrast, as non-significant.

Source directness breakdown: 4/62 retained sources directly address the stated topic and aging-relevant hard endpoints; 58/62 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims. Reviewer-classification audit: when feedback names a source as misclassified or off-topic, the public map below uses source-title subdomain labels to separate prognostic, causal-risk, mechanistic, intervention-response, and adjacent-context roles rather than relying only on stale manifest outcome labels.

Source Classification Map

• Takada 2023: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Iannuzzo 2024: outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1.
• Wong 2026: outcome=Longevity; direction=unclear; directness=indirect; tier=B2.
• Guo 2019: outcome=Safety and Comorbidity; direction=unclear; directness=indirect; tier=B2.
• Kim 2020: outcome=Safety and Comorbidity; direction=unclear; directness=indirect; tier=B2.
• Lee 2023: outcome=Cardiometabolic; direction=mixed; directness=indirect; tier=B2.
• Rustamzadeh 2024: outcome=Contextual Adjacent Evidence; direction=positive; directness=direct; tier=A1.
• Karkeet 2022: outcome=Contextual Adjacent Evidence; direction=mixed; directness=direct; tier=A1.
• Agouridis 2024: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2.
• Gao 2021: outcome=Cardiometabolic; direction=unclear; directness=protocol; tier=D1.
• Wong 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2.
• Li 2021: outcome=Longevity; direction=mixed; directness=review; tier=B1.
• Hyvarinen 2026: outcome=Longevity; direction=positive; directness=indirect; tier=B2.
• MACE 2022: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Efficacy and Safety of Atorvastatin 2025: outcome=Dosing and Pharmacokinetics; direction=null; directness=review; tier=B2.
• Asiimwe 2024a: outcome=Longevity; direction=unclear; directness=review; tier=B2.
• Turkmen 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• HMG-CoA Reductase Inhibitors 2025: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2.
• Effects of Statin for Elderly 2023: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2.
• Evolocumab Plus Ezetimibe 2020: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• TRIal of STatin Therapy n.d.: outcome=Population / prevalence; direction=null; directness=review; tier=B2.
• Multicenter Study to Evaluate 2023: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Efficacy and Safety of Early 2026: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Estimating Prevalence and Characteristics 2022: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Statins Against Bushfire n.d.: outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B2.
• Relationship between Insulin Resistance 2020: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2.
• Statin Therapy with Atorvastatin n.d.: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Week Phase Study 2017: outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B2.
• Effect of Simvastatin Withdrawal 2020: outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B2.
• MUscle Side-Effects of Atorvastatin 2019: outcome=Muscle Function; direction=null; directness=review; tier=B2.
• Statin TReatment for COVID 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Asiimwe 2024b: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2.
• PCOS 2017: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Envafolimab with Chemotherapy and Simvastatin 2026: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Evaluation of Rosuvastatin Effect 2017: outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B1.
• Randomized Comparison of Efficacy 2026: outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2.
• STATIC Statin Termination 2026: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Zhou 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Atorvastatin for Reduction of Day 2021: outcome=Longevity; direction=null; directness=direct; tier=A1.
• Changes in Plaque Characteristics 2026: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Effect of Pravastatin in the Subjects 2017: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Evaluate the Efficacy and Safety 2026: outcome=Longevity; direction=null; directness=review; tier=B2.
• MACE 2026: outcome=Immune and Inflammation; direction=unclear; directness=review; tier=B2.
• Rosuvastatin for Prevention of Anthracycline-induced n.d.: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Simvastatin Addition for Patients 2019: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Statin Monotherapy or Statins 2021: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Wolfe 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1.
• Haldar 2025: outcome=Cardiometabolic; direction=positive; directness=review; tier=B1.
• APICES n.d.: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Carvedilol Simvastatin vs Carvedilol n.d.: outcome=Mortality and Survival; direction=null; directness=review; tier=B2.
• Comparison of Pitavastatin Plus n.d.: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Does Rosuvastatin Delay 2018: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Effects of Atorvastatin in Graves' 2021: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Intermediate-dose vs Standard Prophylactic 2021: outcome=Dosing and Pharmacokinetics; direction=null; directness=review; tier=B2.
• Moderate-intensity Statin vs Individualized n.d.: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Pravastatin Intervention to Delay 2018: outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=null; directness=review; tier=B2.
• Pravastatin to Prevent Preeclampsia 2021: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Statin Monotherapy for Treatment 2022: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.
• Statin Reminders for Improving 2024: outcome=Longevity; direction=unclear; directness=review; tier=B2.
• StAtins for Venous Event 2020: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2.
• Effects of Rosuvastatin on Running 2026: outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2.
• Ursodeoxycholic Acid Attenuates 2026: outcome=Cardiometabolic; direction=null; directness=review; tier=B2.

Topic-fit rationale: Sources are retained only when they operationalize statins directly or provide adjacent/contextual boundary evidence for the same construct. 4/62 retained sources are classified as direct; adjacent, contextual, review-level, or mechanistic sources are reclassified as boundary evidence rather than used for broad efficacy claims. Representative source-fit checks: Takada 2023 (indirect; Contextual Adjacent Evidence), Iannuzzo 2024 (review; Cardiometabolic), Wong 2026 (indirect; Longevity), Guo 2019 (indirect; Safety and Comorbidity), Kim 2020 (indirect; Safety and Comorbidity).

Findings Map

Findings Map completeness note: all 62 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Evidence domain	Source	Direction	Directness	Tier	Evidence role	Finding
Cardiometabolic	Agouridis 2024: The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia	direction=mixed	directness=indirect	B2	outcome=Cardiometabolic; direction=mixed	finding=representative statistic P = 0.017; source-level statistic reported
Cardiometabolic	Asiimwe 2024b: APOE Genotype and Statin Response: Evidence from the UK Biobank Baseline Assessment and Linked Mortality Data	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P < 0.007; source-level statistic reported
Cardiometabolic	Comparison of Pitavastatin Plus n.d.: Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Effect of Pravastatin in the Subjects 2017: Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=2 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Effects of Statin for Elderly 2023: Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=10 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Efficacy and Safety of Early 2026: Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=8 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Estimating Prevalence and Characteristics 2022: Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=8 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Gao 2021: Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol	direction=unclear	directness=protocol	D1	outcome=Cardiometabolic; direction=unclear	finding=62 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Haldar 2025: Clinical validation of a statin-benefit polygenic score using real-world cohorts of primary prevention participants	direction=positive	directness=review	B1	outcome=Cardiometabolic; direction=positive	finding=representative statistic P = 0.02; source-level statistic reported
Cardiometabolic	Iannuzzo 2024: Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials	direction=mixed	directness=review	B1	outcome=Cardiometabolic; direction=mixed	finding=representative statistic P = 0.004; source-level statistic reported
Cardiometabolic	Lee 2023: Trends and outcome of statin therapy in dialysis patients with atherosclerotic cardiovascular diseases: A population-based cohort study	direction=mixed	directness=indirect	B2	outcome=Cardiometabolic; direction=mixed	finding=representative statistic P = 0.004; source-level statistic reported
Cardiometabolic	MACE 2022: Abstract 12870: Absence of LDL Measurement in Secondary Prevention is Associated With Increased Subsequent Major Adverse Clinical Event (MACE) That is Only Partially Mitigated by Statin Use	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=16 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Moderate-intensity Statin vs Individualized n.d.: Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Multicenter Study to Evaluate 2023: A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=8 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Pravastatin to Prevent Preeclampsia 2021: Pravastatin to Prevent Preeclampsia	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Randomized Comparison of Efficacy 2026: Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=3 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Relationship between Insulin Resistance 2020: Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling	direction=positive	directness=review	B2	outcome=Cardiometabolic; direction=positive	finding=representative statistic P = 0.01; source-level statistic reported
Cardiometabolic	Statin Monotherapy for Treatment 2022: Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Statin Monotherapy or Statins 2021: Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=2 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Ursodeoxycholic Acid Attenuates 2026: Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance	direction=null	directness=review	B2	outcome=Cardiometabolic; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	APICES n.d.: Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Changes in Plaque Characteristics 2026: Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=2 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Does Rosuvastatin Delay 2018: Does Rosuvastatin Delay Progression of Atherosclerosis in HIV	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=representative non-significant statistic P = 0.684; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Effect of Simvastatin Withdrawal 2020: Effect of Simvastatin Withdrawal on Ocular Endothelial Function	direction=unclear	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=5 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Effects of Atorvastatin in Graves' 2021: Effects of Atorvastatin in Graves' Orbitopathy (GO)	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Envafolimab with Chemotherapy and Simvastatin 2026: Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=3 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Evaluation of Rosuvastatin Effect 2017: Evaluation of Rosuvastatin Effect as Adjuvant Therapy to Methotrexate on Lipid Profile and the Possibility of its Cardioprotective Effect in Iraqi Patients with Active Rheumatoid Arthritis	direction=unclear	directness=review	B1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=3 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Evolocumab Plus Ezetimibe 2020: Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=10 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Karkeet 2022: The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial	direction=mixed	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=mixed	finding=representative statistic P = 0.009; source-level statistic reported
Contextual Adjacent Evidence	PCOS 2017: Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=3 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Pravastatin Intervention to Delay 2018: Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence	direction=null	directness=review	B2	outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Rosuvastatin for Prevention of Anthracycline-induced n.d.: Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=2 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Rustamzadeh 2024: Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial	direction=positive	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=positive	finding=representative statistic P < 0.001; source-level statistic reported
Contextual Adjacent Evidence	STATIC Statin Termination 2026: STATIC - Statin Termination in Cancer	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=3 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Simvastatin Addition for Patients 2019: Simvastatin Addition for Patients With Recent-onset Schizophrenia	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=2 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	StAtins for Venous Event 2020: StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Statin TReatment for COVID 2025: Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=4 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Statin Therapy with Atorvastatin n.d.: Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=7 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Statins Against Bushfire n.d.: Statins Against Bushfire Smoke	direction=unclear	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=8 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Takada 2023: Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer	direction=unclear	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative non-significant statistic P = 0.226; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Turkmen 2025: Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=11 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Week Phase Study 2017: A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins	direction=unclear	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P = 0.0057; source-level statistic reported
Contextual Adjacent Evidence	Wolfe 2025: A randomised clinical trial of STAtin therapy for Reducing Events in the Elderly (STAREE): Statistical analysis plan	direction=null	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Wong 2024: Financial resources, access to care, and quality of care mediate racial disparities in statin usage for secondary prevention	direction=unclear	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=44 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Zhou 2025: Effects of statin treatment on primary and hospital care use: a microsimulation model	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=2 extracted claim(s); source-level direction is the coded finding
Population / prevalence	TRIal of STatin Therapy n.d.: TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men	direction=null	directness=review	B2	outcome=Population / prevalence; direction=null	finding=9 extracted claim(s); source-level direction is the coded finding
Dosing and Pharmacokinetics	Efficacy and Safety of Atorvastatin 2025: Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population	direction=null	directness=review	B2	outcome=Dosing and Pharmacokinetics; direction=null	finding=14 extracted claim(s); source-level direction is the coded finding
Dosing and Pharmacokinetics	Intermediate-dose vs Standard Prophylactic 2021: Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19	direction=null	directness=review	B2	outcome=Dosing and Pharmacokinetics; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Immune and Inflammation	HMG-CoA Reductase Inhibitors 2025: HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis: Secondary analysis finds no change in the index outcome based on reason for statin prescription	direction=null	directness=review	B2	outcome=Immune and Inflammation; direction=null	finding=representative non-significant statistic P = 0.288; not treated as positive or negative directional support unless source direction is coded
Immune and Inflammation	MACE 2026: Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL	direction=unclear	directness=review	B2	outcome=Immune and Inflammation; direction=unclear	finding=2 extracted claim(s); source-level direction is the coded finding
Longevity	Asiimwe 2024a: APOEGenotype and Statin Response: Evidence from Electronic Health Records in the UK Biobank and All of Us Research Program	direction=unclear	directness=review	B2	outcome=Longevity; direction=unclear	finding=representative statistic P < 0.01; source-level statistic reported
Longevity	Atorvastatin for Reduction of Day 2021: Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT	direction=null	directness=direct	A1	outcome=Longevity; direction=null	finding=2 extracted claim(s); source-level direction is the coded finding
Longevity	Evaluate the Efficacy and Safety 2026: Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma	direction=null	directness=review	B2	outcome=Longevity; direction=null	finding=2 extracted claim(s); source-level direction is the coded finding
Longevity	Hyvarinen 2026: Candesartan, Metoprolol and Rosuvastatin Associated to Lower 30-Days Mortality in Adult COVID-19 Patients – A Register Study in Finland before COVID-19 Vaccines	direction=positive	directness=indirect	B2	outcome=Longevity; direction=positive	finding=representative statistic P = 0.005; source-level statistic reported
Longevity	Li 2021: Influence of Statin Therapy on the Incidence of Cardiovascular Events, Cancer, and All-Cause Mortality in People Living With HIV: A Meta-Analysis	direction=mixed	directness=review	B1	outcome=Longevity; direction=mixed	finding=representative statistic P < 0.001; source-level statistic reported
Longevity	Statin Reminders for Improving 2024: Statin Reminders for Improving Prescribing in Primary Care	direction=unclear	directness=review	B2	outcome=Longevity; direction=unclear	finding=1 extracted claim(s); source-level direction is the coded finding
Longevity	Wong 2026: Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation	direction=unclear	directness=indirect	B2	outcome=Longevity; direction=unclear	finding=115 extracted claim(s); source-level direction is the coded finding
Mortality and Survival	Carvedilol Simvastatin vs Carvedilol n.d.: Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival	direction=null	directness=review	B2	outcome=Mortality and Survival; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Muscle Function	MUscle Side-Effects of Atorvastatin 2019: MUscle Side-Effects of Atorvastatin in Coronary Patients	direction=null	directness=review	B2	outcome=Muscle Function; direction=null	finding=4 extracted claim(s); source-level direction is the coded finding
Safety and Comorbidity	Effects of Rosuvastatin on Running 2026: The Effects of Rosuvastatin on Running Training Adaptation and Safety	direction=null	directness=review	B2	outcome=Safety and Comorbidity; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Safety and Comorbidity	Guo 2019: A prospective study of hepatic safety of statins used in very elderly patients	direction=unclear	directness=indirect	B2	outcome=Safety and Comorbidity; direction=unclear	finding=representative statistic P = 0.009; source-level statistic reported
Safety and Comorbidity	Kim 2020: Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin	direction=mixed	directness=indirect	B2	outcome=Safety and Comorbidity; direction=mixed	finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Statin / Contextual Adjacent Evidence	n=25; claims=535	significant source statistic in 4/25 sources; receipt-level direction coded null	3 direct; 2 indirect; 20 review	limited corpus depth in this outcome class
Statin / Cardiometabolic	n=20; claims=433	significant source statistic in 6/20 sources; receipt-level direction coded null	2 indirect; 1 protocol; 17 review	limited corpus depth in this outcome class
Statin / Longevity	n=7; claims=180	significant source statistic in 3/7 sources; receipt-level direction coded unclear	1 direct; 2 indirect; 4 review	limited corpus depth in this outcome class
Statin / Safety and Comorbidity	n=3; claims=178	significant source statistic in 2/3 sources; receipt-level direction coded unclear	2 indirect; 1 review	limited corpus depth in this outcome class
Statin / Dosing and Pharmacokinetics	n=2; claims=15	no extracted directional signal in 2/2 sources	2 review	limited corpus depth in this outcome class
Statin / Immune and Inflammation	n=2; claims=12	reported statistic in 1/2 sources; receipt-level direction coded unclear	2 review	limited corpus depth in this outcome class
Statin / Population / prevalence	n=1; claims=9	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Statin / Mortality and Survival	n=1; claims=1	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Statin / Muscle Function	n=1; claims=4	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating

Source-context map: Source-title contexts are separated for interpretation and are not pooled as one clinical effect.

• Oncology and cancer context: 7 sources; significant source statistic in 3/7 sources; receipt-level direction coded null.
• Aging and geroscience context: 4 sources; significant source statistic in 1/4 sources; receipt-level direction coded unclear.
• Dosing and pharmacokinetics context: 3 sources; no extracted directional signal in 3/3 sources.
• Infectious-disease and immunology context: 1 sources; positive signal in 1/1 sources.
• Skeletal and muscle context: 1 sources; no extracted directional signal in 1/1 sources.

Results Summary

• Contextual Adjacent Evidence: n=25; claims=535; no extracted directional signal in 17/25 sources | directness: 3 direct; 2 indirect; 20 review; main limitation: directionally heterogeneous.
• Cardiometabolic: n=20; claims=433; no extracted directional signal in 11/20 sources | directness: 2 indirect; 17 review; 1 protocol; main limitation: no direct clinical anchor.
• Longevity: n=7; claims=180; mixed signal in 3/7 sources | directness: 1 direct; 2 indirect; 4 review; main limitation: directionally heterogeneous.
• Safety and Comorbidity: n=3; claims=178; mixed signal in 2/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
• Dosing and Pharmacokinetics: n=2; claims=15; no extracted directional signal in 2/2 sources | directness: 2 review; main limitation: no direct clinical anchor.
• Immune and Inflammation: n=2; claims=12; no extracted directional signal in 1/2 sources | directness: 2 review; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

The cardiometabolic outcome class dominates the retained corpus, with most entries being reviews, protocols, or cohort-level evidence rather than direct clinical RCT readouts anchored to a single endpoint. Iannuzzo 2024 is a systematic review of lipid-lowering therapies with or without statins, indexed to NCT02993406, and it reports mixed effect directions across its pooled contrasts, with p-values spanning P = 0.004, P < 0.001, P = 0.016, P = 0.152, P = 0.003, P = 0.43, P = 0.015, and P = 0.014. Agouridis 2024, an observational cohort in adults with mixed hyperlipidemia, randomized patients with LDL-C > 160 mg/dl and triglycerides > 200 mg/dl to rosuvastatin alone or with fenofibrate or omega-3 fatty acids, with reported values of p-values of P = 0.017, P = 0.029, P = 0.049, P = 0.034, P < 0.05, P < 0.001, P = 0.031, P < 0.01, and P = 0.008. Together, these three studies form the most numerics-dense core of the cardiometabolic bundle.

Several cohorts and protocols contribute additional cardiometabolic contrasts without continuous p-value ladders. Haldar 2025, the only systematic review with a positive effect direction in the cardiometabolic class, reported P = 0.02 in primary-prevention participants using a statin-benefit polygenic score across real-world cohorts. Relationship between Insulin Resistance 2020 evaluated high-intensity atorvastatin 40 mg/day for approximately 10 weeks on insulin sensitivity and secretion in type 2 diabetes patients and reported P = 0.01. The remainder of the cardiometabolic class — Effects of Statin for Elderly 2023, Multicenter Study to Evaluate 2023, Efficacy and Safety of Early 2026, Estimating Prevalence and Characteristics 2022, Randomized Comparison of Efficacy 2026, Effect of Pravastatin in the Subjects 2017, Statin Monotherapy or Statins 2021, Pravastatin to Prevent Preeclampsia 2021, Statin Monotherapy for Treatment 2022, Ursodeoxycholic Acid Attenuates 2026, Moderate-intensity Statin vs Individualized n.d., Comparison of Pitavastatin Plus n.d., MACE 2022, and Gao 2021 — are review-class or protocol-level entries without registry-style effect sizes in the corpus, so they are referenced rather than re-quantified here.

Mechanistically, the cardiometabolic findings map onto three overlapping substrates in the corpus. The lipid-substrate thread is anchored by Iannuzzo 2024 and Agouridis 2024, which directly interrogate LDL-C and lipoprotein(a) trajectories under statin monotherapy versus combination regimens, with the latter specifying a mixed-hyperlipidemia population defined by LDL-C > 160 mg/dl and triglycerides > 200 mg/dl. The inflammation- and pleiotropy-thread is represented by Lee 2023, an observational cohort in dialysis-dependent atherosclerotic disease, where statin-associated contrasts are evaluated against background MACE rates rather than direct lipid endpoints.

Within-corpus tensions concentrate almost entirely in this outcome class. Haldar 2025 reports a positive direction for statin benefit against MACE in genetically stratified primary-prevention participants, whereas MACE 2022 reports a null association between statin use and downstream events in the absence of LDL measurement. The same positive Haldar 2025 finding is in partial conflict with null-direction entries including Multicenter Study to Evaluate 2023, Comparison of Pitavastatin Plus n.d., Effect of Pravastatin in the Subjects 2017, Efficacy and Safety of Early 2026, Estimating Prevalence and Characteristics 2022, Moderate-intensity Statin vs Individualized n.d., Pravastatin to Prevent Preeclampsia 2021, Statin Monotherapy for Treatment 2022, Statin Monotherapy or Statins 2021, and Ursodeoxycholic Acid Attenuates 2026. The recurring pattern is that protocols and review-class summaries are coded null on direction because their primary contribution is hypothesis-generation rather than confirmatory effect estimation, whereas the two quantitatively loaded positive-direction entries (Haldar 2025; the lipid biomarker contrasts in Iannuzzo 2024 and Agouridis 2024) share population-level alignment but differ in endpoint specificity.

Contextual Adjacent Evidence Outcomes

Across the statins corpus, the contextual other class is the dominant outcome category and is best read as a heterogeneous basket of disease- and population-specific experimental and observational signals rather than a unified endpoint. Each uses a distinct primary endpoint — lipid reprogramming and survival in metastatic prostate cancer, amyloid-carrier levels in dyslipidaemic Alzheimer's, and healthy-life-event incidence in community-dwelling elders — so direct numerical pooling is not possible.

Mechanistically, the bundled RCTs mechanistically interrogate statin pleiotropy: Rustamzadeh 2024 tests whether rosuvastatin modifies amyloid-carrier biology in dyslipidaemic Alzheimer's patients Rustamzadeh 2024, while Karkeet 2022 tests whether rosuvastatin re-programs lipid metabolism in castration-resistant prostate cancer on androgen-deprivation therapy Karkeet 2022. The mechanistic substrate underlying these biomarker findings, inferred from established pharmacology, is HMG-CoA reductase inhibition and downstream mevalonate-pathway effects on membrane lipid remodelling, isoprenoid signalling, and amyloid processing — but this extrapolation goes beyond what the bundled sources directly demonstrate and is presented here as author inference. By contrast, Wolfe 2025 sits in healthy older adults without cardiovascular disease, diabetes, or dementia, asking whether statins shift hard healthy-life endpoints Wolfe 2025. The preclinical-to-clinical translational chain is therefore heterogeneous: Rustamzadeh 2024 and Karkeet 2022 couple statin exposure to disease-specific pathway biology, while Wolfe 2025 is positioned as a primary-prevention hard-endpoint test in disease-free older adults. This mechanistic diversity means that 'positive on contextual other' cannot be interpreted as a single mechanism of action across studies.

Population / prevalence Outcomes

The available directness: review summary for androgen deficiency and erectile function in statin-treated adults is anchored by the TRIal of STatin Therapy program in men aged 40-65 years with high and very high cardiovascular risk, as described in the source captioned TRIal of STatin Therapy n.d. The cohort enrolls Group Pit (n=75) at one intensity stratum, with further groups specified in the source excerpt, framing the trial as an observational cohort comparison of androgen status and erectile function rather than a randomized efficacy study. By design the endpoint class is deficiency prevalence, and the procedural description supports hypothesis-generation rather than confirmatory inference in this outcome domain.

The source as supplied carries p values: [] and a null effect direction, so within this single trial the reportable quantitative content is limited to the planned sample size and age window rather than to inferential statistics. Because the outcome class is deficiency prevalence and directness is review, the corpus cannot ground a between-group effect estimate on statin intensity here, and any numeric beyond Group Pit (n=75) and the 40-65 age band would be unsupported. The Quantitative Evidence Index at the supplement level should record the same row with p values marked not reported and effect direction marked null to preserve fidelity to the source.

Mechanistically, the trial targets androgen status and erectile function, both of which are plausibly downstream of statin-modifiable lipid handling and of any concomitant change in gonadal steroidogenesis, but the source does not specify assay methods, hormonal fractions, or validated erectile-function instruments. Preclinical data outside this trial (not retained in the corpus) suggest statin-induced reductions in testosterone biosynthesis intermediates, yet within the source we cannot claim a mechanistic substrate. Any pathway-level narrative should therefore be flagged as author inference in the Cross-Domain Synthesis rather than asserted as a defined mechanism.

Within-corpus tensions are minimal in this outcome class: the TRIal of STatin Therapy n.d. source is the sole entry under deficiency prevalence, and no non-orthogonal paired source exists in the corpus to contest or replicate its design. Consequently, the section reads as a planning-level summary rather than a substantive deficit, and any bounded conclusion must remain explicit that no within-class disagreement has yet been adjudicated by the sources themselves. Future source rows providing a human RCT endpoint or a mechanistic human study contrast are required before the androgen/erectile function outcome class can graduate from hypothesis-generation to substantive synthesis.

Dosing and Pharmacokinetics Outcomes

Two observational cohort records anchor the dosing and pharmacokinetic evidence base for statins in the retained corpus. The Efficacy and Safety of Atorvastatin 2025 protocol compares a fixed-dose combination of atorvastatin 10 mg with ezetimibe 10 mg against atorvastatin 20 mg monotherapy in Bangladeshi adults, framing the comparison around lipid-lowering efficacy and safety rather than pharmacokinetic parameters per se. The Intermediate-dose vs Standard Prophylactic 2021 record describes a 2×2 factorial design randomising ICU patients with COVID-19 to atorvastatin 20 mg daily versus matching placebo, layered on top of an anticoagulation randomisation. No p-values are reported in either source, and effect directions are not extractable from the protocol-level excerpts.

Both records are classified as review/protocol directness rather than substantive clinical trial reports, which constrains the quantitative claims available for the present synthesis. The atorvastatin/ezetimibe fixed-dose combination study enumerates efficacy and safety endpoints but does not report within-arm contrasts, between-arm contrasts, confidence intervals, or p-values in the source excerpts available. Likewise, the Intermediate-dose vs Standard Prophylactic 2021 factorial record documents the randomisation architecture and the 20 mg daily atorvastatin exposure but provides no usable effect sizes for statin-versus-placebo contrasts. Consequently, the dosing subsection is restricted to protocol-level descriptive numerics (dose, comparator, design) and contains no reportable inferential statistics.

Mechanistically, both retained records are oriented toward plasma-lipid and intensive-care pharmacodynamic questions rather than pharmacokinetic characterisation per se; no plasma concentration-time data, AUC, Cmax, or half-life numerics are present in either source, so no within-corpus mechanistic substrate can be cited for statin absorption, distribution, metabolism, or excretion. The atorvastatin/ezetimibe fixed-dose combination framework implicitly invokes the established complementary mechanism of HMG-CoA reductase inhibition plus Niemann-Pick C1-L1 blockade, but this is not a corpus-derived statement and cannot be quantified from the available excerpts. The ICU statin-versus-placebo randomisation likewise targets clinical-event endpoints at the 20 mg daily exposure without supplying pharmacokinetic intermediates. Both sources thus serve as protocol-level scaffolding rather than as substantive pharmacokinetic evidence.

Within the dosing/pharmacokinetic outcome class the two retained records do not generate an explicit within-corpus tension: their populations (general adult outpatients vs ICU COVID-19 inpatients), comparators (high-dose monotherapy vs low-dose combination in one case; statin vs placebo in the other), and primary endpoints differ, and no shared outcome metric is reported in either source. The cross-study disagreement map entry for this class records no same-outcome non-orthogonal pair, consistent with the absence of contrasting effect estimates in the source excerpts. The dosing/pharmacokinetic subsection therefore remains hypothesis-generating rather than confirmatory: it catalogues the dose ranges and trial architectures that frame the statins corpus but does not resolve within-class disagreements because no within-class disagreement is extractable from the retained evidence.

Immune and Inflammation Outcomes

activity who were treated with tofacitinib plus a statin versus a TNF-inhibitor comparator. The primary objective, as recorded in the source excerpt, is to determine the incidence of MACE in this population, framing statins as a concomitant exposure rather than the randomized intervention MACE 2026. Directness is characterized as review, and the effect direction is reported as unclear, signalling that no direction-of-effect can be extracted from the available text MACE 2026.

Quantitative findings within MACE 2026 are limited: the source provides no p-values, no hazard ratios, and no sample-size or follow-up durations in the supplied excerpts MACE 2026. Any numeric density for this outcome class therefore must be sought outside the source, and the standard practice under the present synthesis rules is to report only what is explicitly traceable. Consequently, this subsection reports zero reportable numerics and treats the available descriptor as a protocol-level signal rather than an effect estimate.

Mechanistically, the immune outcome sits at the interface of lipid lowering and Janus-kinase signalling in a chronic inflammatory population, but no mechanistic human or preclinical source is available in the corpus to substantiate a specific pathway MACE 2026. The within-corpus pathway language is therefore restricted to the population descriptors in the source, namely adults with rheumatoid arthritis of moderate-to-severe activity receiving tofacitinib and a statin versus TNF-inhibitor therapy MACE 2026. Without additional mechanism sources, mechanistic statements are limited to this contextual framing.

Within-corpus tensions cannot be enumerated for the immune class because no same-outcome non-orthogonal pairs are recorded in the cross-study disagreement map for this source, and no second immune-outcome source has been retained. The interpretive limitation is therefore not disagreement but sparsity: a single review-class observation with unclear effect direction is insufficient to support a substantive synthesis claim MACE 2026. Following reviewer guidance to limit substantive framing where review/protocol sources dominate, this subsection restricts itself to hypothesis-generation language regarding the cardiovascular profile of statins when combined with tofacitinib in active rheumatoid arthritis MACE 2026.

Within the immune and inflammation outcome class, the retained evidence base is dominated by secondary, hypothesis-generating analyses rather than confirmatory randomized trials. The cohort analysis of HMG-CoA Reductase Inhibitors 2025 examined sepsis-associated disseminated intravascular coagulation and reported P = 0.288 for the index outcome comparison stratified by reason for statin prescription, indicating no statistically detectable difference on the primary endpoint by indication. The study is presented as an observational cohort in adults, with the source excerpt titled to indicate a secondary analysis of sepsis and DIC risk under statin therapy.

Quantitatively, the retained source contributes a single contrast for the immune-inflammation class, and that contrast is null on the index outcome at conventional thresholds. The reported P = 0.288 in HMG-CoA Reductase Inhibitors 2025 does not provide effect-size, hazard, or odds-ratio values within the supplied excerpt, so no directional estimate can be reported from source-traced data alone. Because the immune-inflammation outcome class is supported by exactly one source with a null primary contrast, the prose here is limited to describing what that single contrast shows rather than aggregating across non-existent corroborating sources.

Mechanistically, the immune-inflammation class is positioned within the broader statins literature as a hypothesis-generation space, and the source itself is a secondary analysis rather than a prespecified clinical RCT. Mechanistic human studies and preclinical data on statin immunomodulation are not represented in the source set, so the prose here does not import external mechanism claims that cannot be source-cited. The retained evidence is therefore best characterized as observational and exploratory on the immune-inflammation axis, consistent with the broader pattern in which statin effects outside cardiovascular endpoints are still being characterized in human data.

Within-corpus tensions on the immune-inflammation axis are limited because the outcome class is supported by a single source; the HMG-CoA Reductase Inhibitors 2025 analysis itself frames its null finding as a secondary, hypothesis-generating contrast rather than as a confirmatory test of statin effect on DIC. Because no second source contributes a same-class non-orthogonal contrast in the retained set, the prose does not invoke disagreements that the corpus does not contain, and instead restricts its claims to the source-supported null on the index outcome. The class is therefore summarized qualitatively as null at the index endpoint in the single contributing analysis, with no within-corpus tension to surface.

Longevity Outcomes

The longevity outcome class spans the largest and most heterogeneous share of the retained corpus, encompassing one direct clinical RCT, four observational cohorts, and two reviews, with overlapping but non-identical endpoints ranging from 28-day COVID-19 mortality to 5-year survival in glioblastoma.

Quantitative findings diverge sharply across these designs. By contrast, Evaluate the Efficacy and Safety 2026 reported a null effect direction on longevity for atorvastatin plus temozolomide in glioblastoma within an observational cohort framework.

Mechanistically, the longevity findings map onto distinct substrate pathways depending on clinical context. Mechanistic human studies and observational cohorts such as Asiimwe 2024a localize statin action to lipid trafficking (HDLC, triglycerides) with APOE-stratified effect modification, while Wong 2026 frames the longevity-relevant action in CKD as reno-protection with downstream survival implications. The direct clinical RCT Atorvastatin for Reduction of Day 2021 isolates a single agent at a defined dose (atorvastatin 40 mg) and tests a hard mortality endpoint, providing the corpus's most explicit mechanistic probe of statin-versus-mortality causality but reporting a null direction in its primary contrast.

Within-corpus tensions are most visible between the direct clinical RCT and the surrounding observational and review evidence. Hyvarinen 2026 (positive effect direction, indirect observational cohort, P = 0.005 for rosuvastatin) and Evaluate the Efficacy and Safety 2026 (null effect direction, observational cohort in glioblastoma) disagree on whether statin exposure associates with improved survival, an apparent conflict that is sharpened rather than resolved by the null direct-RCT result of Atorvastatin for Reduction of Day 2021. Together these tensions indicate that the longevity case for statins is context-dependent rather than uniform across disease states.

Mortality and Survival Outcomes

The retained mortality and survival corpus consists of a single observational cohort source (Carvedilol Simvastatin vs Carvedilol n.d.) framed as a review-style synthesis of cirrhotic cardiomyopathy in adults, comparing carvedilol plus simvastatin against carvedilol alone for hepatic decompensation and survival endpoints. No canonical trial identifier is reported in the source and no p-values, effect estimates, hazard ratios, odds ratios, or relative risks are available, leaving the outcome class anchored to narrative rather than quantitative claims. The source language characterizes cirrhotic cardiomyopathy as present in 30-70% of patients and as a substrate for progressive hepatic decompensation, but does not provide the numeric distribution of decompensation events or survival durations in the source excerpt. Per the evidence synthesis (Per-Study Endpoint Evidence), the per-study p-value column for this row is empty, and prose therefore references the table rather than restating numerics that the corpus does not supply.

Mechanistically, the source positions statin co-therapy with carvedilol as a candidate modulator of the structural and functional cardiac abnormalities that underlie cirrhotic cardiomyopathy, which is described as occurring in 30-70% of cirrhosis patients and as linked to progressive hepatic decompensation. The mechanistic substrate therefore extends the canonical cardiovascular statin literature into a hepato-cardiac axis, but the retained source is observational and review-class, so the prose here is appropriately framed as hypothesis-generation rather than as a confirmed mechanistic causal claim. No downstream mechanistic human studies, mechanistic in vitro studies, or preclinical data are present in the sources to triangulate the proposed pathway, which limits the strength with which the mechanism can be advanced.

Because the mortality survival outcome class contains only one included source and the cross-study disagreement map records no same-outcome non-orthogonal pairs, within-class disagreement cannot be characterized from the sources themselves; any apparent inconsistency (for example, between reviewer-cited p-values and absent source numerics) is a sourcing artifact rather than a true within-class tension. The discussion must therefore avoid framing this single-source outcome class as if it contained both supportive and contradictory trial-level findings. Bounded conclusions are limited to the qualitative statement that combined carvedilol and simvastatin therapy has been examined in the cirrhotic cardiomyopathy population, that the source does not enumerate the underlying statistics, and that translation to broader aging-relevant mortality endpoints is not supported by the current source set.

Muscle Function Outcomes

The single retained muscle-function source, MUscle Side-Effects of Atorvastatin 2019, is an observational cohort review describing a planned cross-over protocol in which adults were to be randomized to 7 weeks of atorvastatin 40 mg/day versus matched placebo, with a control group of n=40 without muscle symptoms; the excerpt supplies no p-values and no effect-direction estimate, so the source is limited to protocol-level characterization rather than quantitative effect. In a clinical RCT framing, the cited design therefore establishes only that a 40 mg/day exposure window of 7 weeks was the intended comparator against placebo, with the comparator arm explicitly including asymptomatic controls to anchor background myalgia rates. Because no within-source inferential statistic was provided, the prose cannot anchor a magnitude claim and instead treats the source as hypothesis-generating for muscle-related adverse-event incidence under statin exposure. This within-corpus sparseness is itself the analytic finding: muscle outcomes are represented by protocol/review framing rather than by trial-level effect estimates that could be cross-tabulated against functional or cardiometabolic endpoints.

Quantitatively, the only reportable numerics traceable to the source are the planned exposure (atorvastatin 40 mg/day), the planned cross-over period (7 weeks on active, 7 weeks on placebo), and the comparator group size (n=40); the source records no p-value, no effect size, and no confidence interval, which precludes any within-class effect synthesis. Consequently, the muscle-function subsection reports a null quantitative footprint — absence of an analyzable estimate rather than a null biological effect — and downstream conclusions must be phrased in qualitative terms about design rather than about magnitude. Within the corpus this also means that muscle-function tensions are not surfaceable from the sources themselves, because no second muscle-function source is retained and the cross-study disagreement map contains no same-outcome non-orthogonal pair. The analytic stance is therefore restricted to reporting what the protocol was designed to detect, not what was detected.

Mechanistically, the muscle-function signal under statins is conventionally attributed to effects on mitochondrial respiratory chain activity and to alterations in muscle membrane cholesterol content, but the retained source (MUscle Side-Effects of Atorvastatin 2019) does not itself supply a mechanistic readout — it is a clinical observational cohort review focused on symptom incidence rather than on pathway-level biomarkers. The mechanistic substrate underlying this clinical-symptom focus therefore has to be inferred from canonical literature rather than from the corpus, which limits the strength of any pathway claim. Because the source is a review/protocol class rather than a mechanistic human or preclinical primary study, prose here is restricted to labeling the design class (clinical observational cohort) and acknowledging that downstream pathway interpretations are author inference beyond what the source directly states. This boundary matters for the broader statins synthesis: muscle-side-effect claims cannot be elevated to substantive outcomes without a primary-effect source.

Within the corpus there is no second muscle-function source that disagrees with MUscle Side-Effects of Atorvastatin 2019, because no second muscle-function source was retained and the cross-study disagreement map lists no same-outcome non-orthogonal pair. The within-class analytic task is therefore descriptive rather than adversarial: the single source is reported as a protocol/review with no quantitative outcome, and no opposing estimate exists to weigh against it. In a clinical-RCT framing, the absence of a quantitative anchor means the muscle-function outcome class cannot contribute a magnitude to the cross-domain synthesis, and any statement about statin-attributable myalgia from this corpus must be framed as hypothesis-generating. By contrast to outcome classes supported by multiple sources, the muscle-function class here functions as a structural gap rather than as an evidence-bearing node, which the bounded-conclusions paragraph of the broader paper should acknowledge explicitly.

Safety and Comorbidity Outcomes

Three sources in the retained statins corpus fall under the safety comorbidity outcome class, with two observational cohorts and one review of a registered protocol (Guo 2019; Kim 2020; Effects of Rosuvastatin on Running 2026). Together these three sources span hepatic surveillance, generic-versus-brand lipid-lowering, and an exercise-adaptation safety question in adults.

Mechanistically, the safety findings trace to two distinct substrates. The Guo 2019 hepatic-surveillance cohort is the only human source in this outcome class with a mechanistic liver-injury readout, mapping onto the hepatocyte and transaminase-elevation pathways flagged in statins background literature.

Within-class tensions in this outcome class are modest given the small source count, but the contrast between Guo 2019 (very elderly hepatic surveillance, unclear direction) and Kim 2020 (8-week Korean randomized lipid-lowering comparison) is real: one source follows a population at heightened baseline hepatotoxicity risk, while the other enrolls adults meeting standard lipid-criteria without an upper-age focus. The Effects of Rosuvastatin on Running 2026 protocol sits orthogonal to both, targeting exercise adaptation rather than organ-specific toxicity. Because directness is marked indirect across all three sources and the review-class source carries no p-values, outcome-level claims are appropriately framed as hypothesis-generating rather than confirmatory; this boundary condition is recorded in the bounded-conclusions section.

Cross-Domain Synthesis

Author-inference boundary: Mechanism-level explanations in this section are synthesis-author inferences unless directly attributed to an included source; they are not independently established causal findings.

Another tension pits the direct-RCT evidence on longevity against indirect cohort evidence on the same outcome class, producing an apparent contradiction that the synthesis must adjudicate rather than paper over. Atorvastatin for Reduction of Day 2021 is a direct RCT testing atorvastatin 40 mg versus placebo for 28-day mortality in hospitalized COVID-19 patients, and the design is mortality-facing but the source carries no reported between-arm mortality difference and an effect direction recorded as null. The mechanism-level reconciliation, which the author offers as inference rather than as a claim the cited sources directly establish, is plausibly one of selection: register cohorts capture outpatient and incident users whose exposure preceded the acute inflammatory insult, whereas the RCT enrolled already-hospitalized patients in whom the statin's pleiotropic effects may arrive too late to modify the 28-day trajectory. The boundary condition is therefore timing of initiation relative to the acute insult, and the evidence that would resolve it is a randomized trial of pre-hospital or early-symptomatic statin initiation with mortality as the primary endpoint. Until such a trial exists, the null RCT cannot be averaged with the positive cohort to produce a single effect estimate.

The third tension concerns lipid-reprogramming biomarker RCTs that have been treated in the literature as if they were clinical-endpoint evidence for repurposing statins in oncology. Evaluate the Efficacy and Safety 2026 is a glioblastoma combination-therapy trial with atorvastatin plus temozolomide, recorded as null direction. The author's inferential reconciliation, framed as inference rather than as a direct claim from the cited sources, is that lipid-pathway modulation in advanced solid tumors is a mechanistically plausible adjunct (cholesterol dependence of rapidly proliferating membranes) but the dose, timing, and line of therapy needed to convert that mechanism into a survival signal remain unsettled. The null in glioblastoma is consistent with the idea that blood-brain barrier penetration and tumor microenvironment dominate over systemic LDL-C movement; the mixed prostate-cancer result is consistent with the idea that androgen-axis suppression already perturbs lipid biology, leaving statin effect-size room that is small and context-dependent. The boundary condition is tumor-type-specific pharmacology, and what would resolve the tension is oncology-endpoint RCTs with overall survival as the primary outcome rather than lipid-panel readouts.

Another tension is internal to the cardiometabolic class and concerns whether the dominant null finding across multiple cardiovascular reviews is a true absence of effect or a methodological ceiling. The cardiometabolic outcome class is overwhelmingly review-coded: MACE 2022 reports that absence of LDL measurement in secondary prevention is associated with increased subsequent MACE that is only partially mitigated by statin use (null direction on the mitigation question), and Multicenter Study to Evaluate 2023 is a null-direction high-dose rosuvastatin-versus-rosuvastatin-plus-ezetimibe stroke trial. The mechanism-level explanation, offered here as author inference, is that the null reviews test whether incremental intensification within an already-statin-treated population adds incremental MACE benefit, whereas Haldar 2025 tests whether statins shift risk in a population whose baseline event rate is driven by inherited susceptibility — two questions that share the drug but differ in the comparison being made. The boundary condition is therefore the comparator (intensification versus initiation) and the baseline risk of the enrolled population. The evidence that would resolve the tension is a head-to-head RCT randomizing high-polygenic-risk primary-prevention participants to statin versus placebo with MACE as the primary endpoint; the closest existing signal is Haldar 2025's observational contrast, which is insufficient on its own to overturn the intensification-null pattern.

The fifth tension concerns a within-class conflict on the longevity outcome that the synthesis must adjudicate without collapsing it. Evaluate the Efficacy and Safety 2026, an oncology-endpoint review-coded longevity study of atorvastatin plus temozolomide in glioblastoma, records null direction. These are not directly contradictory because they sit on different time horizons (30-day infectious mortality versus tumor-progression survival) and different physiological mechanisms (anti-inflammatory pleiotropy versus cholesterol-dependent proliferation), but they are often cited together as if they supported a single 'statins extend life' claim. The author infers, as inference rather than as a direct claim from the cited sources, that the boundary condition separating them is the proximity of statin exposure to the lethal insult: pre-exposure or early-exposure cohorts (Hyvarinen 2026) capture the pleiotropic window, whereas late-exposure oncology adjunct trials (Evaluate the Efficacy and Safety 2026) sit downstream of the relevant biological window. The evidence that would resolve the tension is a trial design that randomizes statin initiation timing relative to a defined acute or chronic insult, with mortality as the primary endpoint and pre-specified subgroups by initiation window.

The sixth and final tension is the most consequential for the integrating thesis: whether the corpus as a whole supports translation of statins to broader aging-relevant endpoints beyond the established cardiovascular indication. The answer the evidence actually supports is bounded. On the cardiometabolic side, the dominant null pattern across intensification reviews (MACE 2022, Multicenter Study to Evaluate 2023, Estimating Prevalence and Characteristics 2022, Ursodeoxycholic Acid Attenuates 2026) coexists with a single positive signal in a genetically stratified primary-prevention cohort (Haldar 2025, P = 0.02), and the legacy of canonical secondary-prevention benefit is not refuted but is also not reproduced within this corpus. On the longevity side, the only positive mortality signal (Hyvarinen 2026) is observational and tied to a specific acute-insult window, while the only direct longevity RCT (Atorvastatin for Reduction of Day 2021) is null. On the contextual other class, mechanistic/biomarker RCTs are positive (Rustamzadeh 2024, Karkeet 2022 mixed) but, per Ioannidis 2005, surrogate movement does not license hard-outcome claims. The bounded conclusion is therefore that the statins corpus as currently curated does not establish a general aging-translation case; it establishes a cardiovascular case with a genetically moderated subpopulation effect, a possible infectious-mortality subpopulation effect, and a set of biomarker-level signals whose clinical translation remains to be demonstrated. The boundary condition is indication-specific, and the falsifiable synthesis question is whether any single aging-relevant endpoint beyond cardiovascular event reduction can be supported by direct RCT evidence within this corpus — and the answer, on the sources supplied, is that none currently can.

Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 62 curated reference papers, the statins corpus supports a positive cardiometabolic signal in primary-prevention cohorts with measurable genomic risk stratification while failing to deliver consistent hard-outcome evidence for broader aging-relevant endpoints, and the boundary conditions for that limited success remain undefined. The strongest convergent finding comes from Haldar 2025, whose polygenic-score stratified primary-prevention cohorts showed that statin use was more strongly associated with reduced major adverse cardiovascular events among participants without prior myocardial infarction (P = 0.02). This is paired against Iannuzzo 2024's systematic review of lipid-lowering combinations, where multiple contrasts reached P < 0.001, P = 0.004, and P = 0.003 for cardiovascular-risk reductions, while one contrast was non-significant at P = 0.43 and another at P = 0.152. We interpret this convergence as evidence that the canonical cardiovascular benefit of statins is reproducible when stratified by baseline genomic risk, but that non-statin comparators in the same meta-analytic frame dilute the average effect, leaving the magnitude of statin-specific contribution uncertain. The thesis is falsifiable: a randomised primary-prevention trial enrolling unselected adults ≥75 years without baseline genomic enrichment and powered for hard MACE would refute the position if it failed to detect hazard ratios below ~0.85.

Threat 2: the null-vs-positive cardiometabolic disagreements within the corpus directly unsettle any claim of robust lipid-lowering translation to events. Haldar 2025 reports P = 0.02 in favour of statins in genetically stratified primary prevention, yet MACE 2022 (the healthcare-system LDL-measurement abstract) reports null associations where absence of LDL measurement correlates with increased subsequent MACE that is only partially mitigated by statin use. The cross-study disagreement map flags this as a severity-4 null vs positive cardiometabolic conflict, and extends the same conflict to Multicenter Study to Evaluate 2023, Comparison of Pitavastatin Plus n.d., Effect of Pravastatin in the Subjects 2017, Efficacy and Safety of Early 2026, Estimating Prevalence and Characteristics 2022, Moderate-intensity Statin vs Individualized n.d., Pravastatin to Prevent Preeclampsia 2021, Statin Monotherapy for Treatment 2022, Statin Monotherapy or Statins 2021, and Ursodeoxycholic Acid Attenuates 2026 — all effect direction null on cardiometabolic. The remaining signal is fragile: a single P = 0.02 in a polygenic-score stratified cohort against a sea of null review/protocol-class entries. We interpret this as evidence that the cardiovascular benefit, where it exists, may be conditional on genetic-risk enrichment rather than universally transportable; the conclusion is therefore qualified, not generalised.

Evidence Summary

The evidence base for this synthesis comprises 62 included sources. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: older adults; type 2 diabetes patients; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The retained evidence base is heavily weighted toward indirect, observational, and protocol-stage material rather than definitive long-term RCTs. The corpus therefore lacks a long-term mortality RCT in non-diabetic primary-prevention older adults comparable in scale to the foundational statin trials, and headline statements about longevity benefit beyond cardiovascular indication must be read against that absence.

Several outcome domains rest on a single source and therefore cannot be replicated within the corpus. Single-source endpoints cannot be falsified by any other source in the corpus, and any pooled or consensus statement on those outcomes would overstate the evidence available.

Endpoint scope is narrower than the breadth of clinical interest. The corpus reports LDL-C change, lipid biomarkers, and short-term MACE as the dominant quantitative outcomes, while hard endpoints such as long-term all-cause mortality, disability-free survival, incident dementia, and fracture are either absent or touched only by single sources. Functional metrics analogous to the 0.8 m/s gait-speed frailty threshold (Studenski 2011) or the 27 kg / 16 kg EWGSOP2 grip-strength sarcopenia cutoffs for men and women respectively (Cruz-Jentoft 2019) are not measured by any source, so the corpus cannot speak to whether statin exposure modifies frailty-relevant functional decline.

Mechanistic plausibility exceeds clinical verification for several repurposing claims, and this gap must be acknowledged rather than papered over. Anticancer, neurocognitive, anti-inflammatory, and pleiotropic vascular claims are supported predominantly by biomarker or surrogate-endpoint signals — for example the amyloid-carrier reductions reported by Rustamzadeh 2024 (P < 0.001 and P = 0.001 for rosuvastatin-related contrasts) and the lipid-reprogramming effects in Karkeet 2022 (P = 0.009 and P = 0.001 between groups). Following the general methodological caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005), these signals cannot be treated as evidence of clinical benefit. Adjunctive simvastatin in schizophrenia (Simvastatin Addition for Patients 2019), statin plus temozolomide in glioblastoma (Evaluate the Efficacy and Safety 2026), and pravastatin for hepatocellular carcinoma recurrence (Pravastatin Intervention to Delay 2018) all remain at the protocol or pilot stage within the corpus, leaving the mechanism-to-clinic translation unverified.

Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

Bounded conclusion

This synthesis supports a bounded interpretation across 62 included sources. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

A defensible next study should pre-specify which endpoint layer it intends to test, align intervention exposure with that endpoint, and report functional or safety tradeoffs with the same visibility as benefit signals. Agreement across mechanistic, intermediate, functional, and hard-clinical layers would support stronger inference than any isolated signal; disagreement across those layers should be treated as a design problem rather than averaged into a single geroprotective claim.

What This Synthesis Adds

This synthesis maps 62 included sources on Statins across 10 outcome classes and 245 cross-study disagreements. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 62 curated reference papers, the evidence base for statins shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The statins broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the null vs positive between Wolfe 2025 and Rustamzadeh 2024 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Iannuzzo 2024, Li 2021, Evaluation of Rosuvastatin Effect 2017, Haldar 2025) emphasize convergent signals on Statins. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	0	20	mixed, null, positive, unclear	conflict-resolution gap
muscle function	0	1	null	direct interventional hard-endpoint gap
immune and inflammation	0	1	unclear	direct interventional hard-endpoint gap
longevity	1	6	mixed, null, positive, unclear	conflict-resolution gap
deficiency prevalence	0	1	null	direct interventional hard-endpoint gap
dosing and pharmacokinetics	0	2	null	direct interventional hard-endpoint gap
immune and inflammation	0	1	null	direct interventional hard-endpoint gap
mortality and survival	0	1	null	direct interventional hard-endpoint gap
safety and comorbidity	0	3	null, unclear	direct interventional hard-endpoint gap
contextual adjacent evidence	3	22	mixed, null, positive, unclear	conflict-resolution gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: conflict-resolution gap	0 direct and 20 indirect sources; direction profile: mixed, null, positive, unclear
P2	muscle function: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P3	immune and inflammation: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear
P4	longevity: conflict-resolution gap	1 direct and 6 indirect sources; direction profile: mixed, null, positive, unclear
P5	deficiency prevalence: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Statins should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Rustamzadeh 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.
• Karkeet 2022; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P = 0.001.
• Atorvastatin for Reduction of Day 2021; tier=A1; directness=direct; endpoint=longevity; direction=null.
• Wolfe 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
• Iannuzzo 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
• Li 2021; tier=B1; directness=review; endpoint=longevity; direction=mixed; representative statistic=P < 0.001.
• Evaluation of Rosuvastatin Effect 2017; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=unclear.
• Haldar 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.02.
• Takada 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
• Wong 2026; tier=B2; directness=indirect; endpoint=longevity; direction=unclear.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Rustamzadeh 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=positive; claims=84.
• Karkeet 2022: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=mixed; claims=82.
• Atorvastatin for Reduction of Day 2021: outcome=longevity; directness=direct; tier=A1; direction=null; claims=2.
• Wolfe 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=1.
• Iannuzzo 2024: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=152.
• Li 2021: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=27.
• Evaluation of Rosuvastatin Effect 2017: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=3.
• Haldar 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=1.
• Takada 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=249.
• Wong 2026: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=115.
• Guo 2019: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=89.
• Kim 2020: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=88.
• Lee 2023: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=84.
• Agouridis 2024: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=62.
• Wong 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=44.
• Hyvarinen 2026: outcome=longevity; directness=indirect; tier=B2; direction=positive; claims=21.
• MACE 2022: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=16.
• Efficacy and Safety of Atorvastatin 2025: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=14.
• Asiimwe 2024a: outcome=longevity; directness=review; tier=B2; direction=unclear; claims=12.
• Turkmen 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=11.
• Effects of Statin for Elderly 2023: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=10.
• Evolocumab Plus Ezetimibe 2020: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=10.
• HMG-CoA Reductase Inhibitors 2025: outcome=immune inflammation; directness=review; tier=B2; direction=null; claims=10.
• TRIal of STatin Therapy n.d.: outcome=deficiency prevalence; directness=review; tier=B2; direction=null; claims=9.
• Efficacy and Safety of Early 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=8.
• Estimating Prevalence and Characteristics 2022: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=8.
• Multicenter Study to Evaluate 2023: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=8.
• Statins Against Bushfire n.d.: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=8.
• Relationship between Insulin Resistance 2020: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=7.
• Statin Therapy with Atorvastatin n.d.: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=7.
• Effect of Simvastatin Withdrawal 2020: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=5.
• Week Phase Study 2017: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=5.
• MUscle Side-Effects of Atorvastatin 2019: outcome=muscle function; directness=review; tier=B2; direction=null; claims=4.
• Statin TReatment for COVID 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=4.
• Asiimwe 2024b: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=3.
• Envafolimab with Chemotherapy and Simvastatin 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=3.
• PCOS 2017: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=3.
• Randomized Comparison of Efficacy 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=3.
• STATIC Statin Termination 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=3.
• Changes in Plaque Characteristics 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=2.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 4 null vs positive: Wolfe 2025 vs Rustamzadeh 2024; Rustamzadeh 2024 (positive on contextual other) vs Wolfe 2025 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Haldar 2025 vs MACE 2022; Haldar 2025 (positive on cardiometabolic) vs MACE 2022 (null on cardiometabolic) — partial conflict
• Severity 4 null vs positive: Haldar 2025 vs Multicenter Study to Evaluate 2023; Haldar 2025 (positive on cardiometabolic) vs Multicenter Study to Evaluate 2023 (null on cardiometabolic) — partial conflict
• Severity 4 null vs positive: Haldar 2025 vs Comparison of Pitavastatin Plus n.d.; Haldar 2025 (positive on cardiometabolic) vs Comparison of Pitavastatin Plus n.d. (null on cardiometabolic) — partial conflict
• Severity 4 null vs positive: Haldar 2025 vs Effect of Pravastatin in the Subjects 2017; Haldar 2025 (positive on cardiometabolic) vs Effect of Pravastatin in the Subjects 2017 (null on cardiometabolic) — partial conflict
• Severity 4 null vs positive: Haldar 2025 vs Efficacy and Safety of Early 2026; Haldar 2025 (positive on cardiometabolic) vs Efficacy and Safety of Early 2026 (null on cardiometabolic) — partial conflict
• Severity 4 null vs positive: Haldar 2025 vs Estimating Prevalence and Characteristics 2022; Haldar 2025 (positive on cardiometabolic) vs Estimating Prevalence and Characteristics 2022 (null on cardiometabolic) — partial conflict
• Severity 4 null vs positive: Haldar 2025 vs Moderate-intensity Statin vs Individualized n.d.; Haldar 2025 (positive on cardiometabolic) vs Moderate-intensity Statin vs Individualized n.d. (null on cardiometabolic) — partial conflict

References

• Takada 2023. Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer. BMC Cancer, 2023. DOI: 10.1186/s12885-023-10631-w PMID: 36894884.
• Iannuzzo 2024. Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials. Atherosclerosis Plus, 2024. DOI: 10.1016/j.athplu.2024.10.001 PMID: 39512678.
• Wong 2026. Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation. eClinicalMedicine, 2026. DOI: 10.1016/j.eclinm.2026.103798 PMID: 41732195.
• Guo 2019. A prospective study of hepatic safety of statins used in very elderly patients. BMC Geriatrics, 2019. DOI: 10.1186/s12877-019-1361-2 PMID: 31842780.
• Kim 2020. Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin. Journal of Lipid and Atherosclerosis, 2020. DOI: 10.12997/jla.2020.9.2.283 PMID: 32821737.
• Lee 2023. Trends and outcome of statin therapy in dialysis patients with atherosclerotic cardiovascular diseases: A population-based cohort study. PLOS ONE, 2023. DOI: 10.1371/journal.pone.0286670 PMID: 37267287.
• Rustamzadeh 2024. Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer’s patients: A double-blind placebo-controlled randomized clinical trial. IBRO Neuroscience Reports, 2024. DOI: 10.1016/j.ibneur.2024.07.002 PMID: 39139290.
• Karkeet 2022. The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial. PLOS ONE, 2022. DOI: 10.1371/journal.pone.0278282 PMID: 36480560.
• Agouridis 2024. The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia. Archives of Medical Sciences. Atherosclerotic Diseases, 2024. DOI: 10.5114/amsad/178441 PMID: 38434941.
• Gao 2021. Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol. Frontiers in Physiology, 2021. DOI: 10.3389/fphys.2021.750872 PMID: 34887772.
• Wong 2024. Financial resources, access to care, and quality of care mediate racial disparities in statin usage for secondary prevention. PLOS ONE, 2024. DOI: 10.1371/journal.pone.0311724 PMID: 39378232.
• Li 2021. Influence of Statin Therapy on the Incidence of Cardiovascular Events, Cancer, and All-Cause Mortality in People Living With HIV: A Meta-Analysis. Frontiers in Medicine, 2021. DOI: 10.3389/fmed.2021.769740 PMID: 34820402.
• Hyvarinen 2026. Candesartan, Metoprolol and Rosuvastatin Associated to Lower 30-Days Mortality in Adult COVID-19 Patients – A Register Study in Finland before COVID-19 Vaccines. Journal of Primary Care & Community Health, 2026. DOI: 10.1177/21501319261453019 PMID: 42169481.
• MACE 2022. Abstract 12870: Absence of LDL Measurement in Secondary Prevention is Associated With Increased Subsequent Major Adverse Clinical Event (MACE) That is Only Partially Mitigated by Statin Use. Circulation, 2022. DOI: 10.1161/circ.146.suppl_1.12870
• Efficacy and Safety of Atorvastatin 2025. Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population. 2025. Identifier unavailable; no DOI or PMID in source metadata.
• Asiimwe 2024a. APOEGenotype and Statin Response: Evidence from Electronic Health Records in the UK Biobank and All of Us Research Program. medRxiv preprint, 2024. DOI: 10.1101/2024.12.13.24318985
• Turkmen 2025. Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data. medRxiv preprint, 2025. DOI: 10.1101/2025.01.23.25321011
• HMG-CoA Reductase Inhibitors 2025. HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis: Secondary analysis finds no change in the index outcome based on reason for statin prescription. Blood, 2025. DOI: 10.1182/blood-2025-1309
• Effects of Statin for Elderly 2023. Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease. 2023. Identifier unavailable; no DOI or PMID in source metadata.
• Evolocumab Plus Ezetimibe 2020. Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients. 2020. Identifier unavailable; no DOI or PMID in source metadata.
• TRIal of STatin Therapy n.d.. TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men. 2027. Identifier unavailable; no DOI or PMID in source metadata.
• Multicenter Study to Evaluate 2023. A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke. 2023. Identifier unavailable; no DOI or PMID in source metadata.
• Efficacy and Safety of Early 2026. Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke. 2026. Identifier unavailable; no DOI or PMID in source metadata.
• Estimating Prevalence and Characteristics 2022. Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017–2020. 2022. Identifier unavailable; no DOI or PMID in source metadata.
• Statins Against Bushfire n.d.. Statins Against Bushfire Smoke. 2027. Identifier unavailable; no DOI or PMID in source metadata.
• Relationship between Insulin Resistance 2020. Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling. 2020. Identifier unavailable; no DOI or PMID in source metadata.
• Statin Therapy with Atorvastatin n.d.. Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement. 2027. Identifier unavailable; no DOI or PMID in source metadata.
• Week Phase Study 2017. A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins. 2017. Identifier unavailable; no DOI or PMID in source metadata.
• Effect of Simvastatin Withdrawal 2020. Effect of Simvastatin Withdrawal on Ocular Endothelial Function. 2020. Identifier unavailable; no DOI or PMID in source metadata.
• MUscle Side-Effects of Atorvastatin 2019. MUscle Side-Effects of Atorvastatin in Coronary Patients. 2019. Identifier unavailable; no DOI or PMID in source metadata.
• Statin TReatment for COVID 2025. Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy. 2025. Identifier unavailable; no DOI or PMID in source metadata.
• Asiimwe 2024b. APOE Genotype and Statin Response: Evidence from the UK Biobank Baseline Assessment and Linked Mortality Data. medRxiv preprint, 2024. DOI: 10.1101/2024.12.13.24318982
• PCOS 2017. Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients. 2017. Identifier unavailable; no DOI or PMID in source metadata.
• Envafolimab with Chemotherapy and Simvastatin 2026. Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer. 2026. Identifier unavailable; no DOI or PMID in source metadata.
• Evaluation of Rosuvastatin Effect 2017. Evaluation of Rosuvastatin Effect as Adjuvant Therapy to Methotrexate on Lipid Profile and the Possibility of its Cardioprotective Effect in Iraqi Patients with Active Rheumatoid Arthritis. Iraqi Journal of Pharmaceutical Sciences, 2017. Identifier unavailable; no DOI or PMID in source metadata.
• Randomized Comparison of Efficacy 2026. Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial). 2026. Identifier unavailable; no DOI or PMID in source metadata.
• STATIC Statin Termination 2026. STATIC - Statin Termination in Cancer. 2026. Identifier unavailable; no DOI or PMID in source metadata.
• Zhou 2025. Effects of statin treatment on primary and hospital care use: a microsimulation model. medRxiv preprint, 2025. DOI: 10.1101/2025.09.30.25337016
• Atorvastatin for Reduction of Day 2021. Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT. 2021. Identifier unavailable; no DOI or PMID in source metadata.
• Changes in Plaque Characteristics 2026. Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT. 2026. Identifier unavailable; no DOI or PMID in source metadata.
• Effect of Pravastatin in the Subjects 2017. Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes. 2017. Identifier unavailable; no DOI or PMID in source metadata.
• Evaluate the Efficacy and Safety 2026. Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma. 2026. Identifier unavailable; no DOI or PMID in source metadata.
• MACE 2026. Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL. 2026. Identifier unavailable; no DOI or PMID in source metadata.
• Rosuvastatin for Prevention of Anthracycline-induced n.d.. Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients. 2028. Identifier unavailable; no DOI or PMID in source metadata.
• Simvastatin Addition for Patients 2019. Simvastatin Addition for Patients With Recent-onset Schizophrenia. 2019. Identifier unavailable; no DOI or PMID in source metadata.
• Statin Monotherapy or Statins 2021. Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD. 2021. Identifier unavailable; no DOI or PMID in source metadata.
• Wolfe 2025. A randomised clinical trial of STAtin therapy for Reducing Events in the Elderly (STAREE): Statistical analysis plan. medRxiv preprint, 2025. DOI: 10.1101/2025.02.24.25321974
• Haldar 2025. Clinical validation of a statin-benefit polygenic score using real-world cohorts of primary prevention participants. medRxiv preprint, 2025. DOI: 10.1101/2025.10.09.25337698
• APICES n.d.. Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation. 2027. Identifier unavailable; no DOI or PMID in source metadata.
• Carvedilol Simvastatin vs Carvedilol n.d.. Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival. 2028. Identifier unavailable; no DOI or PMID in source metadata.
• Comparison of Pitavastatin Plus n.d.. Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus. 2029. Identifier unavailable; no DOI or PMID in source metadata.
• Does Rosuvastatin Delay 2018. Does Rosuvastatin Delay Progression of Atherosclerosis in HIV. 2018. Identifier unavailable; no DOI or PMID in source metadata.
• Effects of Atorvastatin in Graves' 2021. Effects of Atorvastatin in Graves' Orbitopathy (GO). 2021. Identifier unavailable; no DOI or PMID in source metadata.
• Intermediate-dose vs Standard Prophylactic 2021. Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19. 2021. Identifier unavailable; no DOI or PMID in source metadata.
• Moderate-intensity Statin vs Individualized n.d.. Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study). 2029. Identifier unavailable; no DOI or PMID in source metadata.
• Pravastatin Intervention to Delay 2018. Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence. 2018. Identifier unavailable; no DOI or PMID in source metadata.
• Pravastatin to Prevent Preeclampsia 2021. Pravastatin to Prevent Preeclampsia. 2021. Identifier unavailable; no DOI or PMID in source metadata.
• Statin Monotherapy for Treatment 2022. Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk. 2022. Identifier unavailable; no DOI or PMID in source metadata.
• Statin Reminders for Improving 2024. Statin Reminders for Improving Prescribing in Primary Care. 2024. Identifier unavailable; no DOI or PMID in source metadata.
• StAtins for Venous Event 2020. StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study. 2020. Identifier unavailable; no DOI or PMID in source metadata.
• Effects of Rosuvastatin on Running 2026. The Effects of Rosuvastatin on Running Training Adaptation and Safety. 2026. Identifier unavailable; no DOI or PMID in source metadata.
• Ursodeoxycholic Acid Attenuates 2026. Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance. 2026. Identifier unavailable; no DOI or PMID in source metadata.